Praxis Precision Medicines, Inc. PRAX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $284.3M+52.7% | $267.12M+75.3% | $245.9M+115% | $221.98M+147% | $186.24M+111% | ||
| $73.03M+33.0% | $59.08M+4.9% | $54.68M+7.0% | $57.37M+28.7% | $54.89M+24.4% | ||
| $357.33M+48.2% | $326.2M+56.3% | $300.57M+81.5% | $279.35M+108% | $241.13M+82.2% | ||
| -$357.33M-53.4% | -$326.2M-63.0% | -$293.11M-78.7% | -$271.59M-105% | -$233.01M-79.0% | ||
| $30.8M+50.6% | $22.93M+32.2% | $20.07M+54.5% | $20.57M+130% | $20.45M+327% | ||
| -$326.53M-53.6% | -$303.27M-65.9% | -$273.04M-80.8% | -$251.01M-103% | -$212.56M-69.5% | ||
| -$13.38-24.1% | -$13.47-30.4% | -$12.96-39.5% | -$12.35-33.4% | -$10.78+27.7% | ||
| -$357.2M-53.5% | -$326.06M-63.2% | -$292.95M-79.1% | -$271.35M-105% | -$232.71M-79.4% | ||
| -$357.33M-53.4% | -$326.2M-63.0% | -$293.11M-78.7% | -$271.59M-105% | -$233.01M-79.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Praxis Precision Medicines, Inc. profitable?
- Praxis Precision Medicines, Inc. is not currently profitable: it reported a net loss of $326.5M over the trailing twelve months, a -3658.5% net margin.
- What is Praxis Precision Medicines, Inc.'s earnings per share?
- Praxis Precision Medicines, Inc.'s diluted EPS over the trailing twelve months is $-13.38.
- Where does Praxis Precision Medicines, Inc.'s income statement data come from?
- Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.